<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892420</url>
  </required_header>
  <id_info>
    <org_study_id>R 87/2021</org_study_id>
    <nct_id>NCT04892420</nct_id>
  </id_info>
  <brief_title>Comparison Between Adjuvants Added to Bupivacaine in Adductor Canal Block</brief_title>
  <official_title>The Effect of Adding Dexamethasone Versus Magnesium Sulphate Versus Dexmedetomidine to Bupivacaine in Ultrasound Guided Adductor Canal Block for Post-operative Analgesia Following Anterior Cruciate Ligament Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients undergoing anterior cruciate ligament repair under Spinal Anaesthesia will be&#xD;
      randomly assigned into one of the following groups (The Four study groups will receive the&#xD;
      standard treatment in the form of spinal anesthesia and adductor canal block), using computer&#xD;
      generated codes and opaque sealed envelopes:&#xD;
&#xD;
        1. Group DX(DEXAMETHASONE): The patients receive 20ml plain bupivacaine (0.5%) + 8 mg&#xD;
           dexamethasone (2ml) in adductor canal block after spinal anaetthesia.&#xD;
&#xD;
        2. Group DM (dexmedetomidine)The patients receive 20 ml plain bupivacaine(0.5)+25 microgram&#xD;
           dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal&#xD;
           anaetthesia.&#xD;
&#xD;
        3. Group M (magnesium sulphate):The patients receive 20 ml plain bupivacaine(0.5)+200&#xD;
           milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after&#xD;
           spinal anaetthesia.&#xD;
&#xD;
        4. Group C(CONTROL): The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal&#xD;
           saline in adductor canal block after spinal anaetthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will clinically be assessed and routine preoperative investigations will be&#xD;
      done; CBC, Coagulation profile, liver function tests, kidney function tests, fasting blood&#xD;
      sugar and ECG.&#xD;
&#xD;
      B. Intraoperative settings:&#xD;
&#xD;
      On arrival of the patients to the operative room, electrocardiography, non-invasive blood&#xD;
      pressure, and pulse oximetry will be applied.&#xD;
&#xD;
      Baseline parameters such as systolic blood pressure (SBP), diastolic blood pressure (DBP),&#xD;
      mean blood pressure (MBP), heart rate (HR), and oxygen saturation (SpO2) will be also&#xD;
      recorded, All patients in this study will be positioned similarly during the entire surgical&#xD;
      procedure and the whole procedures will be done by the same team.&#xD;
&#xD;
      Intravenous (IV) line will be inserted, and IV lactated Ringer will be started.&#xD;
&#xD;
      For all groups, spinal anaesthesia will be performed using spinal needle of 25-G under&#xD;
      complete aseptic conditions All participants will receive spinal anaesthesia using hyperbaric&#xD;
      0.5% bupivacaine 20 mg and fentanyl 25 µg.&#xD;
&#xD;
      ACB will be done in the study at the end of surgery.&#xD;
&#xD;
      Specific equipment required: 22-gauge 100mm length, short-beveled regional block needle, skin&#xD;
      antiseptic solution, sterile gloves, the portable ultrasound machine.&#xD;
&#xD;
      In Group DX:&#xD;
&#xD;
      The patients received 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) Position&#xD;
      patient supine with knee slightly flexed and leg externally rotated&#xD;
&#xD;
        -  Cleaning the area with Povidone-iodine 10% (Betadine), stand to the side of the patient&#xD;
           to be blocked with the ultrasound machine on the opposite side and the screen facing,&#xD;
           placing a high frequency ultrasound probe on the anterior aspect of the patient's thigh,&#xD;
           approximately mid-point between the inguinal crease and medial condyle, Identifying the&#xD;
           femur (usually at a depth of 3-5cm although variable) and move probe medially until the&#xD;
           trapezoid/boat shaped Sartorius' muscle is visualized. The femoral artery lies just&#xD;
           under this muscle within the adductor canal. Considering the saphenous nerve is almost&#xD;
           always too small to be reliably imaged and the aim of the technique is therefore, to&#xD;
           deposit local anesthetic under Sartorius and around the femoral artery (i.e. within the&#xD;
           adductor canal).&#xD;
&#xD;
        -  Optimizing image, adjusting depth, gain and frequency settings as required, the&#xD;
           appropriate probe position is just proximal to where the femoral artery &quot;dives&quot;&#xD;
           posteriorly and the probe should be positioned perpendicular to the artery. At this&#xD;
           point the femoral artery should start to pass deeper to form the popliteal artery, the&#xD;
           vastus medialis muscle lies anterolateral, the adductor magnus muscle posteromedial and&#xD;
           the sartorius muscle medial. Use an in-plane approach from lateral to medial ensuring&#xD;
           that your needle tip can be seen at all times, advance your needle into the adductor&#xD;
           canal. This can be achieved by traversing Sartorius or Vastus Medialis, Aspirate and&#xD;
           inject a test dose of 1 ml of the local anesthetic solution, observe the spread of the&#xD;
           local anesthetic to ensure your needle tip is definitely within the adductor canal. If&#xD;
           you cannot clearly see the spread of local anesthetic consider intravascular placement&#xD;
           of needle and reposition, continue with the injection, aspirating every 5mls.&#xD;
&#xD;
           2-In GROUP DM: 25 microgram dexmedetomidine will be Added.&#xD;
&#xD;
           3-IN GROUP M: 200 milligram magnesium sulphate will be added&#xD;
&#xD;
           4-IN GROUP C (CONTROL): Nothing will be added to bupivacaine.&#xD;
&#xD;
      C. Postoperative settings:&#xD;
&#xD;
      After the patient will be discharged from the operating room. Visual analog scale (VAS) will&#xD;
      be used to assess the postoperative pain;&#xD;
&#xD;
        -  The visual analog scale (VAS) is a validated, subjective measure for acute and chronic&#xD;
           pain. Scores are recorded by making a hand written mark on a 10-cm line that represents&#xD;
           a continuum between &quot;no pain&quot; on the left end (0 cm) of the scale and the &quot;worst pain&quot;&#xD;
           on the right end of the scale (10 cm), and an eight-point verbal rating score for pain&#xD;
           at rest (no pain _ 0, just noticeable _ 1, mild _ 2, weak _ 3, moderate _ 4, strong _ 5,&#xD;
           severe _ 6,excruciating _ 7, same random word display shown to each patient).&#xD;
&#xD;
        -  If VAS ≥ 3 postoperatively, IV increment of morphine will be given 0.1 mg per Kg not to&#xD;
           be repeated every less than 3 hours ,The times of the first request for postoperative&#xD;
           analgesia and the number of injections will be recorded. Any side effects will be&#xD;
           recorded as hypotension (systolic arterial pressure &lt;90 mmHg), arrhythmia, bradycardia&#xD;
           (HR &lt;60 beat/min), nausea or vomiting, or any other complications. Atropine 0.5 mg will&#xD;
           be given in response to bradycardia, 20 ml per kg lactated Ringer will be given in&#xD;
           response to hypotension.&#xD;
&#xD;
        -  If local anaesthetic toxicity occurred, cardiovascular and respiratory support and 20%&#xD;
           intralipid bolus of 100 ml over 2-3 min will be given.&#xD;
&#xD;
        -  HR and MBP will be measured upon arrival to the PACU and after 30 min, then every hour&#xD;
           if the patients remain in the PACU.&#xD;
&#xD;
        -  In the surgical ward, vital signs (HR, SBP, MBP, DBP) as well as pain intensity will be&#xD;
           assessed every 2 hours during the first 6 hours and then every 6 hours there for 24&#xD;
           hours postoperatively. All patients will receive ketorolac 30 mg IM every 8h. It will&#xD;
           start immediately postoperatively in the PACU.&#xD;
&#xD;
      Measurements;&#xD;
&#xD;
      ● Primary outcome:&#xD;
&#xD;
      VAS for pain (ranging from 0 to 10, where 0 no pain and 10 maximum pain) will be evaluated&#xD;
      postoperatively and every 2 hours during the first 6 hours and then every 6 hours there for&#xD;
      24 hours postoperatively&#xD;
&#xD;
      Duration of postoperative analgesia (the time from recovery to the first given dose of&#xD;
      morphine)&#xD;
&#xD;
      Number of patients needed rescue analgesia.&#xD;
&#xD;
      ● Secondary outcome:&#xD;
&#xD;
      The total dose of morphine used postoperatively/patient (rescue analgesia) for 24 h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>using computer generated codes and opaque sealed envelopes:</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>rescue analgesia time</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>time to first analgesic requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rescue analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>total dose of morphine needed postoperatively</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group DX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients receive 20 ml plain bupivacaine(0.5%)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients receive 20 ml plain bupivacaine(0.5%)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.</description>
    <arm_group_label>Group DX</arm_group_label>
    <other_name>decadrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .</description>
    <arm_group_label>Group DM</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.</description>
    <arm_group_label>Group M</arm_group_label>
    <other_name>english salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacain</intervention_name>
    <description>The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>marcain</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-60 years.&#xD;
&#xD;
          2. Sex: Both sexes.&#xD;
&#xD;
          3. Height 155-170 cm.&#xD;
&#xD;
          4. American Society of Anaesthesiologists (ASA) Physical Status Class-I and II.&#xD;
&#xD;
          5. Scheduled for anterior cruciate ligament under spinal anaesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Declining to give written informed consent.&#xD;
&#xD;
          2. History of allergy to the medications used in the study.&#xD;
&#xD;
          3. Contraindications to regional anesthesia (including coagulopathy and local infection).&#xD;
&#xD;
          4. Psychiatric disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ismail md ibrahim, investigator</last_name>
    <phone>01013972871</phone>
    <email>doc_ismail_2006@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohamed ms awad, investigator</last_name>
    <phone>01204227780</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ismail Mohammed Ibrahim</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>ismail md ibrahim, investigator</last_name>
      <phone>01013972871</phone>
      <email>doc_ismail_2006@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>mohamed ms awad, investigator</last_name>
      <phone>0124227780</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ismail Mohammed</investigator_full_name>
    <investigator_title>lecturer of anesthesia</investigator_title>
  </responsible_party>
  <keyword>dexamethasone,</keyword>
  <keyword>magnesium sulphate</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>adductor canal block</keyword>
  <keyword>anterior cruciate ligament repair</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

